The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

Yael Eshet*, Noam Tau, Sara Apter, Noam Nissan, Keren Levanon, Rinat Bernstein-Molho, Ofer Globus, Amit Itay, Tal Shapira, Cecilie Oedegaard, Malka Gorfine, Michal Eifer, Tima Davidson, Einav Gal-Yam, Liran Domachevsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

Original languageEnglish
Pages (from-to)228-232
Number of pages5
JournalClinical Nuclear Medicine
Issue number3
StatePublished - 1 Mar 2023


  • FAPI-04
  • PET/CT
  • breast neoplasms
  • carcinoma
  • lobular


Dive into the research topics of 'The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer'. Together they form a unique fingerprint.

Cite this